Role of gemifloxacin in community-acquired pneumonia

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 4, 2008, Pages 405-418

  Tillotson, Glenn S ^a  

^a NONE   (United States)

Author keywords

Community acquired pneumonia; Fluoroquinolone; Gemifloxacin; Short course therapy

Indexed keywords

10 (8 AMINO 6 AZASPIRO[3.4]OCTAN 6 YL) 9 FLUORO 2,3 DIHYDRO 3 METHYL 7 OXO 7H PYRIDO[1,2,3 DE][1,4]BENZOXAZINE 6 CARBOXYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DV 7751; ENOXACIN; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; TETRACYCLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; NAPHTHYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ENZYME INHIBITION; EOSINOPHILIA; ERADICATION THERAPY; GLYCEMIC CONTROL; HAEMOPHILUS INFLUENZAE; HEADACHE; HEALTH CARE COST; HUMAN; INCIDENCE; LOBAR PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; MACULOPAPULAR RASH; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MORTALITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NECROSIS; NONHUMAN; PHOTOSENSITIVITY; PHOTOTOXICITY; REPEATED DRUG DOSE; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; STREPTOCOCCUS PNEUMONIAE; URTICARIA; VASCULITIS; VERTIGO; VOMITING; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; ECONOMICS; REVIEW;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; NAPHTHYRIDINES; PNEUMONIA, BACTERIAL;

EID: 54449093808     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.4.405     Document Type: Article

References (50)

1. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance. Am. J. Public Health 90, 223-229 (2000).
2. Marrie TJ. Community-acquired pneumonia. Clin. Infect. Dis. 18, 501-513 (1994).
3. Ruiz M, Ewig S, Marcos MA et al. Etiology of community acquired pneumonia: impact of age, comorbidity, and severity. Am. J. Respir. Crit. Care Med. 160, 397-405 (1999).
4. British Thoracic Society. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 56(Suppl. 4), IV1-IV64 (2001).
5. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2), S27-S72 (2007).
6. Marston BJ, Plouffe JF, File TM et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch. Intern. Med. 157, 1709-1718 (1997).
7. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther. 20(4), 820-837 (1998).
8. Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL. Economic burden of pneumonia in an employed population. Arch. Intern. Med. 161(22), 2725-2731 (2001).
9. File TM Jr, Garau J, Blasi F et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 125, 1888-1901 (2004).
10. Echols RM, Tillotson GS, Tosiello R, Song J. Clinical trial design for mild to moderate community acquired pneumonia - an industry perspective. Clin. Infect. Dis. (2008) (In Press).
11. Echols RM, Anderson A. Comparison of etiology of community-acquired pneumonia by Fine class. Presented at: 43rd Annual Meeting of the IDSA, San Diego, CA, USA (2003) (Abstract 519).
12. Felmingham D, Grüneberg RN; The Alexander Project Group. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J. Antimicrob. Chemother. 45, 191-203 (2000).
13. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. 50(Suppl. S1), 25-37 (2002).
14. Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEXT 1999-2003). [i Int. J. Antimicrob. Agents 26(6), 479-485 (2005).
15. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J. Antimicrob. Chemother. 52, 944-952 (2003).
16. Low DE. Resistance trends in Haemophilus influenzae (PROTEKT years 1-3 [1999-20021). J. Chemother. 16(Suppl. 6), 49-61 (2004).
17. Jorgensen JH. Update on mechanisms and prevalence of antimicrobial resistance in Haemophilus influenzae. Clin Infect. Dis. 14(5), 1119-1123 (1992).
18. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN; The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52(2), 229-246 (2003).
19. Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ; CROSS Study Group. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47(6), 1875-1881 (2003).
20. Castanheira M, Gales AC, Mendes RE, Jones RN, Sader HS. Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY antimicrobial surveillance program. Clin. Microbiol. Infect.10, 645-651 (2003).
21. Calca-Mercado JJ, Castillo G, Lopez-Vidal Y. Actividad de las fluoroquinolonas en aislamentos clincos de Streptococcus pneumoniae con diferente susceptibilidad a la penicilina: studio epidemilogico en cinco ciudades de la Republica Mexicana. Gac. Med. Mex. 141, 253-258 (2005).
22. Draghi DC, Jones ME, Sahm DE, Tillotson GS. Geographically-based evaluation of multidrug resistance trends among Streptococcus pneumoniae in the USA: findings of the FAST surveillance initiative (2003-2004). Int. J. Antimicrob. Agents 28(6), 525-531 (2006).
23. Pichichero, ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 298(15), 1772-1778 (2007).
24. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin. Infect. Dis. 31, 1008-1011 (2000).
25. Metlay JP, Kopoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. J. Am. Med. Assoc. 278, 1440-1445 (1997).
26. Garau J. The clinical impact of macrolide resistance in pneurnococcal respiratory infections. Int. J. Antimicrob. Agents 18(Suppl. 1), 33-38 (2001).
27. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35(5), 556-564 (2002).
28. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams. J. Antimicrob. Chemother. 51, 691-696 (2003).
29. Schrag SJ, Peña C, Fernández J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 286(1), 49-56 (2001).
30. File T. Clinical efficacy of newer agents in short duration therapy for community-acquired pneumonia. Clin. Infect. Dis. 39, S159-S164 (2004).
31. Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy and safety. Pharmacotherapy 25(5), 717-740 (2005).
32. Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37, 752-760 (2003).
33. Morrissey I, Tillotson G. Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae. J. Antimicrob. Chemother. 53, 144-148 (2004).
34. Morrissey I, Clark S, Mathias I. The bactericidal activity of gemifloxacin (SB-265805). J. Med. Microbiol. 49(9), 841-844 (2000).
35. Garcia-Olmos M, Parra A, Garcia-Calvo G et al. Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility. Int. J. Antimicrob. Agents 21(6), 568-573 (2003).
36. Azoulay-Dupuis E, Bédos JP, Mohler J et al. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Antimicrob. Agents Chemother. 49, 1046-1054 (2006).
37. Bast DJ, Dresser L, Duncan CL et al. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice. J. Chemother. 18(6), 634-640 (2006).
38. Dresser LD, deAzavedo JCS, Duncan CL, Low DE, Bast DJ. Short-course therapy of gemifloxacin versus moxifloxacin against murine pneumococcal pneumonia caused by a single-step ParC mutant. Presented at: 45th Annual Meeting of IDSA, San Diego, CA, USA (2007) (Abstract 491).
39. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr. Opin. Pharmacol. 1, 459-463 (2001).
40. Saravolatz L, Manzor O, Pawlak J, Belian B. Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae. Int. J. Antimicrob. Agents 26(1), 81-84 (2005).
41. Ball P, File TM, Twynholm M et al. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int. J. Antimicrob. Agents 18, 19-27 (2001).
42. Lode H, File TM Jr, Mandell L, Ball P. Pypstra R, Thomas M; 185 Gemifloxacin Study Group. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin. Ther. 24(11), 1915-1936 (2002).
43. File TM Jr, Schlemmer B, Garau J et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother. 48, 67-74 (2001).
44. Léophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir. Med. 98(8), 708-720 (2004).
45. File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J. Antimicrob. Chemother. 60(1), 112-120 (2007).
46. Gemifloxacin package insert, 2007 (Factive). Oscient Pharmaceuticals, Waltham, MA, USA.
47. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37(11), 1405-1433 (2003).
48. Morrissey I, File TM Jr, Mandell LA, Tillotson G. Patient risk factors in community-acquired pneumonia infections outcome following treatment with gemifloxacin. Presented at: 3rd ISC DMS, Montreal, Canada, September, 2005 (Abstract 19).
49. Morrissey I, File TM Jr, Mandell LA, Tillotson G. Cardio-pulmonary medical history and the effect on clinical outcome of community-acquired pneumonia infections treated with gemifloxacin. Presented at: 3rd ISC DMS, Montreal, Canada, September, 2005 (Abstract 20).
50. Bhavnani SM, Ambrose PG. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 60(1), 59-64 (2008).